For decades in life sciences, pharmacovigilance (PV)—a critical reinforcer of drug safety—has been a reactive function. Its remit has been to collect details of adverse events (side-effects of ...
ZS has been named a Leader in the inaugural IDC MarketScape: Worldwide Life Sciences R&D AI (Including GenAI) in Clinical ...
Hosted on MSN
New generative AI can design drugs for hard diseases
Generative artificial intelligence is moving from the margins of pharma into the center of how new medicines are imagined, built, and tested. Instead of tweaking existing compounds, these models can ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Simulations Plus appears to be a unique Buy candidate, driven by an ultra-low valuation and the potential for AI-inspired growth in drug discovery modeling. The FDA Modernization Act 2.0 and industry ...
Insilico Medicine (03696.HK), a global leader in AI-driven drug discovery and a portfolio company of Qiming Venture Partners, today successfully listed on the Hong Kong Stock Exchange (HKEX). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback